Screener
Allogene Therapeutics ALLO Common Stock Shares Issued
Common Stock Shares Issued at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and Contingencies (Notes 6 and 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares were issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value: 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 244,816,413 and 229,413,523 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 245 | 229 |
| Additional paid-in capital | 2,332,129 | 2,302,753 |
| Accumulated deficit | (2,053,316) | (2,010,709) |
| Accumulated other comprehensive income (loss) | (183) | 269 |
| Total stockholders’ equity | 278,875 | 292,542 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's common stock shares issued?
- Allogene Therapeutics (ALLO) reported common stock shares issued of 244.8M in Q1 2026.
- How has Allogene Therapeutics's common stock shares issued changed year-over-year?
- Allogene Therapeutics's common stock shares issued increased by 12.0% year-over-year, from 218.6M to 244.8M.
- What is the long-term trend for Allogene Therapeutics's common stock shares issued?
- Over 5 years (2020 to 2025), Allogene Therapeutics's common stock shares issued has grown at a 10.3% compound annual growth rate (CAGR), from 140.5M to 229.4M.
- What does common stock shares issued mean?
- The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.
Ask your AI about Allogene Therapeutics's common stock shares issued.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude